Skip to content

Nuvectis Pharma, Inc. NVCT Net Change in Cash

Net Change in Cash at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$635M-220%
Pfizer logo
PfizerPFE
$563M+50.1%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
-$14.68M-734%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$6.28M+332%
Nuvation Bio logo
Nuvation BioNUVB
-$38.7M-416%
Immunome logo
ImmunomeIMNM
-$70.79M-162%

Other financials

Income statement

See full
Operating income-$6.3M-12.4%
Net income-$6.1M-13.5%
EPS (diluted)-$0.26+3.7%

Balance sheet

See full
Cash & equivalents$25.1M-15.9%
Total equity$14.2M-32.1%
Total assets$25.4M-15.8%

Cash flow

See full
Operating cash flow-$6.5M-56.0%

Valuation

See full
Market cap$739.27M+335%

Returns & leverage

See full
Return on equity-154.4%+79.4pp
Current ratio2.3×-1.0×

Where this comes from

Reported directly by Nuvectis Pharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect.

The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvectis Pharma, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvectis Pharma, Inc.'s net change in cash?
Nuvectis Pharma, Inc. (NVCT) reported net change in cash of -$6.5M in Q1 2026.
How has Nuvectis Pharma, Inc.'s net change in cash changed year-over-year?
Nuvectis Pharma, Inc.'s net change in cash decreased by 157.4% year-over-year, from $11.33M to -$6.5M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.